At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 92 enrolled
Drug / intervention
DER 45 EV +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Dose-Range Study of DER 45 EV Gel, 1% and 5%, and Vehicle Gel in the Treatment of Rosacea
In Brief
A Phase 2 clinical trial evaluating DER 45 EV and Vehicle for Rosacea. Completed, enrolled 92 participants across 10 sites.
Detailed Summary
To identify lowest efficacious dose of DER 45 EV Gel, 1% and 5% verses vehicle in patients with rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartJan 2012
Primary CompletionSep 2012
Study CompletionJan 2013
TodayJul 2026
First PostedJul 17, 2009
Enrollment StartJan 1, 2012
Primary CompletionSep 1, 2012
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.0 years ago
Interventions
DER 45 EVdrug
Topical application to face for 12 weeks
Vehicledrug
Topical application to face for 12 weeks